Which has better earnings and valuation, INAB or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is INAB or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Cassava Sciences N/A -53.90% -34.20%

Do analysts prefer EXOZ or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 277.36%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, EXOZ or INAB?

eXoZymes has higher revenue and earnings than IN8bio. eXoZymes is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 621.02 -$9.16M -$1.14 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is EXOZ or INAB more profitable?

IN8bio's return on equity of -96.39% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% IN8bio N/A -96.39% -80.18%

Which has better valuation & earnings, INAB or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is INAB or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Alterity Therapeutics N/A N/A N/A

Which has stronger valuation & earnings, RNXT or INAB?

RenovoRx has higher revenue and earnings than IN8bio. RenovoRx is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 36.80 -$11.17M -$0.33 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is RNXT or INAB more profitable?

IN8bio has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. IN8bio's return on equity of -96.39% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% IN8bio N/A -96.39% -80.18%

IN8bio (INAB) Competitors

$1.06 -0.05 (-4.50%)

As of 10:05 AM Eastern

Compare

INAB vs. FLNA, EXOZ, ATHE, BHST, and RNXT

Should you buy IN8bio stock or one of its competitors? MarketBeat compares IN8bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IN8bio include Cassava Sciences (FLNA), eXoZymes (EXOZ), Alterity Therapeutics (ATHE), BioHarvest Sciences (BHST), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry.

How does IN8bio compare to Cassava Sciences?

IN8bio (NASDAQ:INAB) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

IN8bio has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market.

92.1% of IN8bio shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cassava Sciences had 1 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for IN8bio. Cassava Sciences' average media sentiment score of 1.49 beat IN8bio's score of 1.44 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Cassava Sciences	Positive

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 277.36%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 477.37%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cassava Sciences' return on equity of -53.90% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Cassava Sciences	N/A	-53.90%	-34.20%

Cassava Sciences is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Summary

Cassava Sciences beats IN8bio on 6 of the 11 factors compared between the two stocks.

How does IN8bio compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 277.36%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio's return on equity of -96.39% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
IN8bio	N/A	-96.39%	-80.18%

92.1% of IN8bio shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

eXoZymes has higher revenue and earnings than IN8bio. eXoZymes is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	621.02	-$9.16M	-$1.14	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

eXoZymes has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

In the previous week, IN8bio had 1 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for eXoZymes. IN8bio's average media sentiment score of 1.44 beat eXoZymes' score of 0.93 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Positive
IN8bio	Positive

Summary

IN8bio beats eXoZymes on 9 of the 14 factors compared between the two stocks.

How does IN8bio compare to Alterity Therapeutics?

IN8bio (NASDAQ:INAB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, IN8bio and IN8bio both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 1.87 beat IN8bio's score of 1.44 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Alterity Therapeutics	Very Positive

IN8bio has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 277.36%. Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 190.89%. Given IN8bio's higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Alterity Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Summary

Alterity Therapeutics beats IN8bio on 8 of the 10 factors compared between the two stocks.

How does IN8bio compare to BioHarvest Sciences?

IN8bio (NASDAQ:INAB) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

IN8bio has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than IN8bio. BioHarvest Sciences is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
BioHarvest Sciences	$34.51M	1.33	-$11.14M	-$0.59	N/A

IN8bio has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IN8bio had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for BioHarvest Sciences. IN8bio's average media sentiment score of 1.44 beat BioHarvest Sciences' score of 0.63 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
BioHarvest Sciences	Positive

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 277.36%. BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 326.44%. Given BioHarvest Sciences' higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioHarvest Sciences beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does IN8bio compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

IN8bio has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. IN8bio's return on equity of -96.39% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
IN8bio	N/A	-96.39%	-80.18%

RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

RenovoRx currently has a consensus target price of $8.50, suggesting a potential upside of 828.96%. IN8bio has a consensus target price of $4.00, suggesting a potential upside of 277.36%. Given RenovoRx's stronger consensus rating and higher possible upside, equities analysts clearly believe RenovoRx is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RenovoRx has higher revenue and earnings than IN8bio. RenovoRx is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	36.80	-$11.17M	-$0.33	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. IN8bio's average media sentiment score of 1.44 beat RenovoRx's score of 0.94 indicating that IN8bio is being referred to more favorably in the news media.

Company	Overall Sentiment
RenovoRx	Positive
IN8bio	Positive

Summary

RenovoRx beats IN8bio on 8 of the 15 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.44M	$3.67B	$6.93B	$12.23B
Dividend Yield	N/A	2.11%	2.65%	8.54%
P/E Ratio	-0.41	22.52	27.48	23.62
Price / Sales	N/A	306.34	515.55	87.41
Price / Cash	N/A	163.15	51.57	59.34
Price / Book	0.38	7.91	10.11	5.84
Net Income	-$19.44M	$23.81M	$3.60B	$336.19M
7 Day Performance	-10.92%	-2.81%	-0.90%	-1.06%
1 Month Performance	-24.82%	-7.59%	-3.94%	-5.46%
1 Year Performance	-50.70%	36.57%	21.26%	15.60%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	4.0449 of 5 stars	$1.06 -4.5%	$4.00 +277.4%	-51.4%	$10.44M	N/A	N/A	20	Positive News Upcoming Earnings Short Interest Decrease
FLNA Cassava Sciences	2.2739 of 5 stars	$0.90 0.0%	$5.00 +455.6%	-60.7%	$43.48M	N/A	N/A	20	News Coverage Positive News Earnings Report
EXOZ eXoZymes	0.3021 of 5 stars	$4.64 +2.0%	N/A	-55.6%	$42.73M	N/A	N/A	29
ATHE Alterity Therapeutics	3.5337 of 5 stars	$4.63 -0.6%	$13.00 +180.8%	-14.0%	$41.05M	N/A	N/A	10	Positive News
BHST BioHarvest Sciences	2.6499 of 5 stars	$2.07 +1.9%	$10.00 +383.3%	-71.0%	$40.42M	$34.51M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. FLNA, EXOZ, ATHE, BHST, and RNXT

How does IN8bio compare to Cassava Sciences?

Summary

How does IN8bio compare to eXoZymes?

Summary

How does IN8bio compare to Alterity Therapeutics?

Summary

How does IN8bio compare to BioHarvest Sciences?

Summary

How does IN8bio compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. FLNA, EXOZ, ATHE, BHST, and RNXT

How does IN8bio compare to Cassava Sciences?

Which has more volatility & risk, INAB or FLNA?

Do institutionals & insiders have more ownership in INAB or FLNA?

Does the media favor INAB or FLNA?

Do analysts rate INAB or FLNA?

Is INAB or FLNA more profitable?

Which has better earnings and valuation, INAB or FLNA?

Summary

How does IN8bio compare to eXoZymes?

Do analysts prefer EXOZ or INAB?

Is EXOZ or INAB more profitable?

Do institutionals & insiders believe in EXOZ or INAB?

Which has preferable earnings & valuation, EXOZ or INAB?

Which has more volatility and risk, EXOZ or INAB?

Does the media refer more to EXOZ or INAB?

Summary

How does IN8bio compare to Alterity Therapeutics?

Do insiders and institutionals hold more shares of INAB or ATHE?

Does the media favor INAB or ATHE?

Which has more volatility and risk, INAB or ATHE?

Do analysts recommend INAB or ATHE?

Is INAB or ATHE more profitable?

Which has better valuation & earnings, INAB or ATHE?

Summary

How does IN8bio compare to BioHarvest Sciences?

Is INAB or BHST more profitable?

Which has better earnings & valuation, INAB or BHST?

Which has more volatility & risk, INAB or BHST?

Do insiders & institutionals believe in INAB or BHST?

Does the media prefer INAB or BHST?

Do analysts recommend INAB or BHST?

Summary

How does IN8bio compare to RenovoRx?

Is RNXT or INAB more profitable?

Which has more volatility and risk, RNXT or INAB?

Do analysts prefer RNXT or INAB?

Do insiders and institutionals hold more shares of RNXT or INAB?

Which has stronger valuation & earnings, RNXT or INAB?

Does the media favor RNXT or INAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools